Fig. 4: Antigenic cartography. | Nature Medicine

Fig. 4: Antigenic cartography.

From: Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial

Fig. 4

a, An antigenic map by ref. 25 served as the base map for all antibody landscapes. Virus variants are shown as color-filled circles. Variants with additional substitutions from their root variant are shown as smaller circles. Variants associated with significant outbreaks or pandemic waves are secondarily encircled in red. Individual sera from individuals who were infected are displayed as open squares in the color of their root variant or gray for mRNA-1273 vaccinated sera; small dark squares represent clinical trial participants. One grid unit in the map corresponds to a twofold dilution in the neutralization assay. Within the x and y axes, the map orientation is free as antigenic distances are relative. Small triangles point to sera outside the shown map area. b, Day 1 and day 91 GMT antibody landscapes for individuals who were uninfected and infected in different arms for the three stages. Impulse lines extending from the base map to the landscapes show the GMT against the specific variant. Lower landscapes correspond to day 1 and upper landscapes to day 91 immunity. To interpret landscapes, a day 91 response where the upper landscape is flat indicates the responses to all the variants were equivalent, whereas skewing up or down indicates an uneven response across variants. The landscapes are ordered by height of their GMT against BA.4/5. The surface colors represent study arms: pink, prototype; red, prototype + Omicron BA.1; black, Omicron BA.1; light green, Delta + Omicron BA.1; blue, Beta + Omicron BA.1; purple, Beta + prototype; yellow, Beta.

Back to article page